Business
Kimberly-Clark sells personal-care, family-care and professional tissue and hygiene products under global brands.
Kimberly-Clark remained profitable and cash-generative despite lower revenue, while discontinued operations and the pending Kenvue acquisition make historical and future comparisons unusually complex.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 2.1%Watch
- Profitability — Net income declined 20.6% to $2.021B from $2.545BWatch
- Cash flow — Free cash flow declined 34.8% to $1.639B from $2.513BWatch
- Margins — Operating margin contracted 178 bps to 14.29%Watch
- Accounting — Defensive cash flow with major portfolio changeNote
- Insiders — 1 purchases and 5 salesOK
Where the revenue comes from
Fiscal 2025, as KIMBERLY CLARK CORP reports it. History and quarterly detail are in the app.
- NA$10.8B
- IPC$5.7B
Leadership changes
From KIMBERLY CLARK CORP's own filings, the day they're filed.
- Nelson Urdaneta · departureeff. 2026-05-22
- Andrew S. Drexler · Chief Financial Officer · departureeff. 2025-06-01
- Joseph Romanelli · President · appointmenteff. 2024-11-13
Latest filings
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-05-14
- 8-K · Company announcement2026-05-05
- 10-Q · Quarterly report2026-04-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about KIMBERLY CLARK CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.